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a-MSH-Stimulated Tolerogenic Dendritic Cells
Induce Functional Regulatory T Cells and
Ameliorate Ongoing Skin Inflammation
Matteo Auriemma1,4,5, Thomas Brzoska1,5, Lars Klenner1,2, Verena Kupas1, Tobias Goerge1,2, Maik Voskort1,
Zuotao Zhao1, Tim Sparwasser3, Thomas A. Luger1,2,5 and Karin Loser1,2,5
The neuropeptide a-melanocyte-stimulating hormone (a-MSH) is a well-known mediator of skin pigmentation.
More recently, it has been shown that a-MSH also exerts a strong anti-inflammatory and immunosuppressive
activity. To elucidate the mechanisms underlying a-MSH-induced immunosuppression, we investigated whether
a-MSH affects dendritic cell/T cell communication, as especially this interaction has an important role in the
regulation of immune responses. Here, we show that a-MSH, by binding to MC-1R, induced tolerogenic
dendritic cells, which were capable of expanding CD4þCD25þFoxp3þ regulatory T cells (Tregs) in vitro, as well
as in vivo. Notably, those a-MSH-induced Tregs were functional as they efficiently inhibited cutaneous contact
allergy and ongoing psoriasis-like skin inflammation in mice. Furthermore, a-MSH induced tolerogenic dendritic
cells capable of generating functional Tregs in human blood. Interestingly, human Tregs expanded via
a-MSH-stimulated dendritic cells suppressed the proliferation and cytokine secretion of pathogenic T-helper-17
(Th17) cells from individuals with psoriasis. Taken together, these data indicate that a-MSH induced
immunosuppressive Tregs in vitro and in vivo, which inhibited disease progression in a mouse model of
psoriasis-like skin inflammation and suppressed the activation and proliferation of effector T cells from subjects
with psoriasis.
Journal of Investigative Dermatology (2012) 132, 1814–1824; doi:10.1038/jid.2012.59; published online 15 March 2012
INTRODUCTION
a-MSH is a 13-amino-acid peptide hormone derived by post-
translational processing from the precursor protein pro-
opiomelanocortin, which also encodes for other bioactive
peptide hormones, including ACTH, b- and g-MSH, or
endogenous endorphins such as b-endorphin (Brzoska et al.,
2008). a-MSH can be detected in numerous cell types such as
melanocytes, keratinocytes, epithelial cells, B cells, natural
killer cells, and subsets of T cells (Botchkarev et al., 1999;
Luger et al., 2000; Loser et al., 2010). Although originally
discovered in the pituitary gland and named for its effects on
pigmentation, more recent studies revealed that a-MSH
interacts with immune cells, thereby exerting antimicrobial,
anti-inflammatory, and immunomodulatory activities (Luger
and Brzoska, 2007; Brzoska et al., 2008; Catania et al., 2010).
The biological effects of a-MSH are mediated by binding to
one of five melanocortin receptors, termed MC-1R to MC-5R,
which belong to the superfamily of G-protein coupled
receptors with seven-transmembrane domains (Cone et al.,
1996). Melanocortin receptor ligation by a-MSH leads to the
activation of adenylate cyclase and the subsequent elevation
of intracellular cyclic cAMP levels (Elliott et al., 2004). MC-1R
was the first melanocortin receptor that has been cloned from
melanocytes and was shown to have a crucial role during
pigmentation, as functional mutations of this receptor greatly
influenced fur color in mammals, as well as hair and skin
color in humans (Chhajlani and Wikberg, 1992; Mountjoy
et al., 1992). However, MC-1R is not only expressed in
melanocytes but is also detectable in the majority of non-
melanocytic cell types such as mucosal cells of the gastro-
intestinal tract or immune cells, including macrophages,
monocytes, dendritic cells (DCs), mast cells, and neutrophils
(Andersen et al., 2005; Cooper et al., 2005; Brzoska et al.,
2008). More recently, MC-1R was also found in CD8þ T cells
(Loser et al., 2010), suggesting a widespread function
of this receptor. At least the anti-inflammatory effects of
a-MSH have been linked to MC-1R engagement as mice with
a nonfunctional MC-1R showed a significantly increased
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gastrointestinal inflammation upon a-MSH stimulation in a
model of experimental colitis, whereas a-MSH considerably
improved inflammation in the gut of wild-type controls
(Maaser et al., 2006). Besides ameliorating gastrointestinal
inflammation, a-MSH has been demonstrated to reduce
delayed-type hypersensitivity responses in the skin, and
to inhibit the development of experimental autoimmune
encephalomyelitis or allergic airway inflammation (Grabbe
et al., 1996; Raap et al., 2003; Han et al., 2007), indicating a
rather general role for a-MSH in the regulation of inflamma-
tory immune responses. However, the molecular mechanisms
underlying the anti-inflammatory and immunomodulatory
activities of a-MSH are not completely understood. It has
been shown that the inhibition of NF-kB activation and
translocation, as well as the protection against IkBa
phosphorylation, finally leading to reduced production of
pro-inflammatory cytokines, seems to be critical for the
a-MSH-mediated effects on immune cells (Bo¨hm et al.,
1999; Ichiyama et al., 1999; Hill et al., 2006).
Here, we show that a-MSH induced tolerogenic DCs, as well
as an enhanced capacity to expand functional CD4þCD25þ
Foxp3þ regulatory T cells (Tregs). These Tregs were able to
efficiently suppress the proliferation and cytokine secretion of
pathogenic Th17 effector cells in ongoing psoriasis-like skin
inflammation of mice and in Th17 cells from individuals with
psoriasis.
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Figure 1. a-Melanocyte-stimulating hormone (a-MSH) induces tolerogenic dendritic cells (DCs). (a) Animals were injected with a-MSH or phosphate-buffered
saline (PBS), and 48 hours after elicitation of contact hypersensitivity (CHS) ear swelling was assessed. Data are shown as mean ear swelling±SD and are
representative of 12 mice in each group (*Po0.05 vs. PBS-treated mice). (b) Flow cytometry of T cells from mice injected with PBS or a-MSH (n¼8 mice in each
group) 48 hours after elicitation of CHS. (Left) Representative dot blots and (right) statistical analyses of Foxp3þ cells in regional lymph nodes are shown; cells
are gated for CD4. Foxp3 staining was performed after cell permeabilization (*Po0.05 vs. PBS-treated mice). (c, d) Bone marrow–derived DCs (bmDCs) were
stimulated with a-MSH or PBS, and the expression of (c) CD80, CD86, PD-L1, PD-L2, and (d) CD205 was quantified by flow cytometry or real-time PCR.
Histogram overlays are gated for CD11c, and one representative out of three independent experiments is shown. (e) The IL-10 concentration in culture
supernatants from a-MSH- or PBS-stimulated DCs was quantified using FlowCytomix kits, and IL-10 mRNA levels were analyzed by real-time quantitative PCR
(*Po0.05 vs. PBS-stimulated DCs). (f) DCs from C57BL/6Je/e mice were stimulated with a-MSH, and the expression of CD80, CD86, and CD205 was analyzed
by flow cytometry. Histogram overlays are gated for CD11c, and one representative experiment is shown.
www.jidonline.org 1815
M Auriemma et al.
a-MSH-Induced Tregs Ameliorate Inflammation
RESULTS
a-MSH induces tolerogenic DCs by binding to MC-1R
To investigate the mechanism underlying the anti-inflamma-
tory effects of a-MSH, we performed contact hypersensitivity
(CHS) experiments. As shown in Figure 1, mice injected with
a-MSH before sensitization to DNFB developed a signifi-
cantly reduced ear swelling compared with phosphate-
buffered saline (PBS)-treated controls (Figure 1a), which was
associated with increased levels of Tregs in regional lymph
nodes (Figure 1b). To dissect direct effects of a-MSH on Tregs,
CD4þ T cells from wild-type mice were stimulated with
different concentrations of a-MSH (105 to 1015 M) for 1–7
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Figure 2. a-Melanocyte-stimulating hormone (a-MSH)-stimulated DCs expand functional regulatory T cells (Tregs). (a) CD4þ T cells from cocultures with
a-MSH-stimulated or control DCs were analyzed for the expression of Foxp3, and (left) one representative dot-plot and (right) statistical analyses of four
independent experiments are shown (*Po0.05 vs. CD4þ T cells from cocultures with phosphate-buffered saline (PBS)-stimulated DCs). Foxp3 staining was
performed after cell permeabilization and cells are gated for CD4. (b) CD4þ T cells from cocultures with a-MSH-stimulated or control DCs were analyzed for
the expression of Foxp3, Nrp-1, and CTLA-4 by flow cytometry. CTLA-4 and Foxp3 staining was performed after cell permeabilization, and (top) representative
histogram overlays and (bottom) statistical analyses of four independent experiments are shown (*Po0.05 vs. CD4þ T cells from cocultures with PBS-stimulated
DCs). Cells are gated for CD4þFoxp3þ . (c) The relative mRNA levels of Foxp3, IL-10, Nrp-1, CTLA-4, and TGF-b were quantified in CD4þ T cells from
cocultures with a-MSH- or PBS-stimulated DCs. Data are shown as mean±SD (*Po0.05 vs. CD4þ T cells from cocultures with PBS-stimulated DCs). (d) CD4þ
T cells were purified from cocultures with a-MSH- or PBS-treated DCs, and proliferation assays were performed by stimulating freshly isolated CD4þCD25
T cells with anti-CD3 and anti-CD28 in the absence or presence of CD4þ T cells from cocultures. Mean values of 3H-thymidine incorporation±SD are
shown (*Po0.05 vs. effector T cellsþCD4þ T cells from cocultures with PBS-stimulated DCs). (e) Wild-type (wt) mice were injected with CD4þ T cells
from cocultures with a-MSH- or PBS-stimulated DCs 24hours before induction of contact allergy. Data are shown as mean ear swelling assessed 48 hours
after elicitation of contact hypersensitivity (CHS) and are representative of 15 mice in each group (*Po0.05 vs. transfer of CD4þ T cells from cocultures
with PBS-stimulated DCs). (f) CD4þ T cells were cocultured with a-MSH- or PBS-stimulated DCs. Subsequently, the numbers of Foxp3þHeliosþ and
Foxp3þHelios Tregs were quantified by flow cytometry. Cells are gated for CD4; Foxp3 and Helios staining was performed after cell permeabilization; and
one representative experiment is shown. c.p.m., counts per minute.
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days. However, none of these assays resulted in the
upregulation of Treg numbers or the induction of suppressive
activity (Supplementary Figure S1a and b online), indicating
that a-MSH had no direct effect on CD4þ T cells and
suggesting that the expansion of Tregs during CHS might
rather be an indirect effect of a-MSH. As tolerogenic DCs
have been described to induce functional Tregs (Mahnke
et al., 2003; Loser et al., 2006), we stimulated bone
marrow–derived DCs (bmDCs) with a-MSH and assessed
the DC phenotype. Compared with PBS-treated controls, a-
MSH-stimulated DCs showed a reduced expression of CD80
and CD86, but increased levels of the negative co-stimulatory
B7-family molecules PD-L1 and PD-L2 (Figure 1c). More-
over, a-MSH-stimulated DCs expressed elevated levels of
CD205 and IL-10 (Figure 1d and e), markers characteristic for
tolerogenic DCs (Adler and Steinbrink, 2007; Mahnke et al.,
2007). As not only the induction of a tolerogenic phenotype
but also the decreased expression of IL-12 or IL-23 might
contribute to immunosuppressive DC functions (Gee et al.,
2009), we quantified these cytokines in PBS- and a-MSH-
stimulated DCs. However, a-MSH did not affect the secretion
of IL-12 or IL-23 (Supplementary Figure S2 online), suggesting
a minor role of IL-12 and IL-23 deprivation for the
immunosuppressive effects of a-MSH.
As signaling via MC-1R has been implicated in the
immunosuppressive activity of a-MSH (Brzoska et al.,
2008), we analyzed the a-MSH-mediated induction of
tolerogenic DCs in C57BL/6Je/e mice characterized by a
point mutation in theMC-1R gene, leading to a nonfunctional
receptor (Robbins et al., 1993). However, a-MSH neither
induced the downregulation of maturation markers nor the
upregulation of CD205 and IL-10 in bmDCs from C57BL/6Je/e
mice (Figure 1f and data not shown), indicating that binding
of a-MSH to a functional MC-1R seems to be crucial for the
induction of tolerogenic DCs.
a-MSH-stimulated DCs generate functional Tregs
Next, CD4þ T cells were cocultured with a-MSH-stimulated
DCs or PBS-treated controls and, subsequently, Treg numbers
were quantified. Interestingly, in cocultures with a-MSH-
stimulated DCs, we identified 2-fold increased levels of
Foxp3þ cells expressing high levels of markers associated
with Treg function, such as CTLA-4, IL-10, TGF-b, or Nrp-1
(Figure 2a–c). Furthermore, Tregs expanded by a-MSH-
stimulated DCs were immunosuppressive in vitro and
in vivo, as they inhibited the proliferation of activated
CD4þCD25 effector T cells (Figure 2d) and reduced the
development of CHS upon adoptive transfer into sensitized
mice (Figure 2e). Using a transwell system or neutralizing
soluble factors such as IL-10 or TGF-b revealed that both
direct cell contact and immunosuppressive cytokines were
responsible for the inhibitory effect of Tregs induced by a-
MSH-stimulated DCs (Supplementary Figure S3 online).
To scrutinize whether a-MSH-treated DCs mediated the
induction of Tregs from conventional CD4þCD25 T cells
rather than the expansion of pre-existing Tregs, thymic-
derived Foxp3þHeliosþ and peripherally induced
Foxp3þHelios Tregs (Thornton et al., 2010) were quantified
in cocultures. Whereas the numbers of Foxp3þHeliosþ Tregs
were similar in both groups, we observed upregulated
levels of Foxp3þHelios Tregs when CD4þ T cells were
cocultured with a-MSH-stimulated DCs compared with
PBS-stimulated DCs (3.2±0.5% in cocultures with PBS-
stimulated DCs vs. 9.7±0.3% in cocultures with a-MSH-
stimulated DCs; Figure 2f). Moreover, Ki-67 staining revealed
an increased proliferation index in Foxp3þHelios T cells
from cocultures with a-MSH-treated DCs versus PBS-treated
DCs (Supplementary Figure S4a online), suggesting that
a-MSH-treated DCs mediate the peripheral induction of Tregs.
To analyze whether a-MSH-stimulated DCs induced Tregs
from conventional CD4þ T cells in vivo, DEREG mice
(Lahl et al., 2007) were treated with diphtheria toxin to
deplete Tregs and inoculated with PBS- or a-MSH-stimulated
DCs. Interestingly, Treg numbers were increased in recipients
of a-MSH-treated DCs compared with controls and, further-
more, induced Helios Tregs showed an enhanced prolifera-
tion as evidenced by BrdU incorporation (Supplementary
Figure S4b and c online), thus supporting that a-MSH-
stimulated DCs favor the de novo induction of Tregs.
a-MSH ameliorates ongoing psoriasis by inducing functional
Tregs in vivo
As an impaired suppressor function of Tregs has been
associated with the progression of psoriasis (Sugiyama
et al., 2005; Yun et al., 2010), we investigated whether the
a-MSH-mediated induction of functional Tregs might ame-
liorate ongoing psoriasis-like skin inflammation. Therefore,
mice were topically treated with imiquimod (van der Fits
et al., 2009) and injected with a-MSH or an equal amount of
anti-tumor necrosis factor-a (TNF-a) because TNF-a blockade
represents an approved treatment of psoriasis (Sabat et al.,
2007; Nestle et al., 2009). Notably, compared with controls,
recipients of a-MSH showed a significant reduction in skin
inflammation, which was similar to mice that received anti-
TNF-a (Figure 3a). This was paralleled by the in vivo
induction of tolerogenic DCs in a-MSH-treated mice as
evidenced by the decreased expression of CD80 and CD86,
as well as the upregulation of IL-10 in major histocompat-
ibility complex class IIþ cells (Figure 3b and data not
shown). Moreover, treatment of psoriatic mice with a-MSH
resulted in 2-fold increased numbers of Foxp3þ Tregs in
regional lymph nodes (placebo-treated mice: 9.9±2.1%;
imiquimod-treated miceþPBS: 11.1±3.0%; imiquimod-
treated miceþa-MSH: 26.8±2.4%; imiquimod-treated mi-
ceþ anti-TNF-a: 17.2±1.8%; Figure 3c), which secreted
high levels of IL-10 (Figure 3c), suggesting that a-MSH indeed
generated functional Tregs in vivo by the induction of
tolerogenic DCs.
In psoriasis, pathogenic Th17 cells are crucial for disease
progression (van der Fits et al., 2009; Clark, 2010). Thus, we
investigated whether a-MSH-induced Tregs might inhibit the
proliferation or cytokine secretion of Th17 cells. As shown in
Figure 3d, psoriatic mice that received a-MSH exhibited
decreased numbers of CD4þ T cells expressing IL-17
compared with recipients of PBS. Furthermore, CD4þ T cells
from a-MSH-treated mice showed reduced mRNA levels
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of IL-17, IL-22, or the Th17-specific transcription factor
RORgt (Figure 3e), indicating that a-MSH-induced Tregs
might indeed have inhibited the proliferation and cytokine
secretion of pathogenic Th17 cells. It is worth mentioning
that the effect of a-MSH on Th17 cell numbers and cytokine
secretion was comparable to that of systemic anti-TNF-a
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treatment (Figure 3d and e). Taken together, these data
indicate that a-MSH, via binding to MC-1R, generated
tolerogenic DCs, which induced functional Tregs able to
suppress the activity of pathogenic Th17 cells in vivo, thus
resulting in the amelioration of ongoing imiquimod-induced
psoriasis.
Ex vivo–generated a-MSH-stimulated DCs ameliorate
psoriasis-like skin inflammation
Next, we analyzed whether ex vivo–generated a-MSH-
stimulated DCs were able to ameliorate ongoing psoriasis
by inducing functional Tregs in vivo. Therefore, a-MSH-
stimulated bmDCs from Thy1.1þ donors were injected into
imiquimod-treated Thy1.2þ recipients. It is worth noting that
the tolerogenic phenotype of adoptively transferred DCs was
conserved in vivo as demonstrated by flow cytometry and
real-time quantitative PCR of re-isolated Thy1.1þ DCs at day
9 after the start of imiquimod treatment. Moreover, injected
Thy1.1þ DCs migrated to regional lymph nodes but were not
detectable in cutaneous lesions (data not shown). In contrast
to controls, injection of a-MSH-stimulated DCs significantly
reduced erythema and epidermal thickness in imiquimod-
treated recipients and induced Tregs in regional lymph
nodes (Figure 4a and b). These Tregs inhibited the IL-17
secretion in CD4þ T cells and potentially also the migration
of pathogenic Th17 cells from draining lymph nodes to
lesional skin (Figure 4b), indicating that ex vivo-generated
a-MSH-treated DCs were able to reduce disease severity by
expanding functional Tregs in vivo.
a-MSH-stimulated human DCs induce immunosuppressive
Tregs
To investigate the relevance of a-MSH/MC-1R signaling for
the induction of tolerogenic human DCs, we characterized the
phenotype of a-MSH- versus PBS-stimulated HLA-DRþ DCs.
Notably, a-MSH treatment resulted in a reduced expression of
CD80 and CD86, as well as an upregulation of IL-10 (Figure
5a). Similar to mouse bmDCs, a-MSH-stimulated human DCs
expanded functional Tregs, as 2-fold increased numbers of
Foxp3þ T cells, which efficiently suppressed the proliferation
of activated CD4þCD25 effector T cells, were detectable
in cocultures with a-MSH-stimulated DCs compared with
PBS-treated DCs (Figure 5b and c). It is worth mentioning that
the a-MSH-mediated induction of tolerogenic DCs and
expansion of immunosuppressive Tregs was dependent on
MC-1R ligation, as stimulation of HLA-DRþ DCs from
individuals with variants in the MC-1R gene, known to
compromise receptor function (Loser et al., 2010), neither
resulted in the downregulation of maturation markers nor the
generation of Tregs upon coculture with CD4þ T cells (Figure
5d and data not shown).
Tregs expanded by a-MSH-stimulated DCs suppressed the
proliferation of pathogenic Th17 cells from individuals with
psoriasis
Next, we investigated whether Tregs induced by a-MSH-
stimulated DCs are able to suppress the activity of Th17 cells
from individuals with psoriasis. It is worth noting that, also in
peripheral blood from individuals with psoriasis, a-MSH
stimulation generated tolerogenic DCs as shown by the
induction of IL-10 and the downregulation of maturation
markers (Supplementary Figure S5 online and data not
shown). Interestingly, upon coculture with CD4þ T cells
from the same individuals, a-MSH-stimulated DCs induced
functional, immunosuppressive Tregs (Figure 6a and b).
To analyze whether Tregs generated by a-MSH-stimulated
DCs inhibited the proliferation and cytokine secretion in
Th17 cells from individuals with psoriasis, we cocultured
CD4þ T cells with a-MSH-stimulated DCs and quantified IL-
17þ cells. As shown in Figure 6c, substantial amounts of
CD4þ IL-17þ T cells were detectable in cocultures with
control DCs, whereas the numbers of Th17 cells decreased
significantly when CD4þ T cells were cocultured with a-
MSH-stimulated DCs, thus suggesting that Tregs induced by
a-MSH-treated DCs might suppress Th17 activity. This was
further strengthened by the decreased expression of IL-17, IL-
22, and RORc (markers that are implicated in the pathogeni-
city of Th17 cells; Ma et al., 2008) in CD4þ T cells from
individuals with psoriasis that have been cocultured with
a-MSH-stimulated DCs (Figure 6d). To confirm that indeed
Tregs induced by a-MSH-stimulated DCs inhibited Th17
activity, we purified CD4þ T cells from cocultures with
a-MSH- or PBS-treated DCs and mixed them with freshly
isolated CD4þ T cells from peripheral blood of individuals
with psoriasis. Interestingly, in contrast to T cells from
cocultures with control DCs, CD4þ T cells from cocultures
with a-MSH-stimulated DCs significantly decreased the
numbers of Th17 cells (Figure 6e), indicating that a-MSH
reduced the activity of Th17 cells from individuals with
psoriasis by the induction of tolerogenic DCs and functional
Tregs. Furthermore, these data suggest that a-MSH might
represent a potential, to our knowledge previously unre-
ported, therapeutic alternative for the treatment of psoriasis.
Figure 3. a-Melanocyte-stimulating hormone (a-MSH) ameliorates ongoing psoriasis by inducing regulatory T cells (Tregs). (a) Typical skin pathologies of
BALB/c mice topically treated with imiquimod for 8 days and injected intravenously (i.v.) with a-MSH or anti-tumor necrosis factor-a (TNF-a) (n¼8 mice in
each group). Hematoxylin and eosin (H&E) staining of skin tissue: original magnification  200, bar¼ 25mm. (b) DCs from regional lymph nodes of mice
injected with a-MSH expressed elevated levels of IL-10. Cells are gated for major histocompatibility complex (MHC-IIþ ), and IL-10 staining was performed after
cell permeabilization. One representative histogram overlay is depicted. (c, left) Increased numbers of Tregs and (right) upregulated IL-10 mRNA expression in
CD4þ T cells from lymph nodes draining cutaneous lesions of a-MSH-treated mice (*Po0.05 vs. injection of phosphate-buffered saline (PBS)). (d) Reduced
Th17 numbers in lymph nodes from a-MSH-injected mice. Cells are gated for CD4, and IL-17 staining was performed after cell permeabilization. (Left) One
representative dot-plot for each group and (right) statistical analyses of % IL-17-expressing CD4þ T cells from regional lymph nodes are shown (*Po0.05 vs.
injection of PBS). (e) a-MSH decreased the expression of Th17-associated genes in CD4þ T cells from lymph nodes draining cutaneous lesions. Relative mRNA
levels of RORgt, IL-17, and IL-22 are shown from n¼ 6 mice in each group (*Po0.05 vs. injection of PBS).
www.jidonline.org 1819
M Auriemma et al.
a-MSH-Induced Tregs Ameliorate Inflammation
Placebo
H&E
Placebo
Imiquimod +
PBS-stim. DC
Imiquimod +
PBS-stim. DC
Imiquimod +
α-MSH-stim. DC
Imiquimod +
α-MSH-stim. DC
Regional
lymph node
Lesional skin
CD4/IL-17/DAPI
Foxp3/CD4/DAPI
Foxp3/CD4
CD4/IL-17
Figure 4. a-Melanocyte-stimulating hormone (a-MSH)-stimulated DCs ameliorate imiquimod-induced psoriasis. (a) Typical skin pathologies of BALB/c mice
treated with imiquimod and injected with Thy1.1þ phosphate-buffered saline (PBS)- or a-MSH-stimulated DCs (n¼8 mice in each group). Hematoxylin and
eosin (H&E) staining of skin tissue: original magnification 200, bar¼25 mm. (b) Immunofluorescence staining of regional lymph nodes and lesional skin
from mice treated with imiquimod and injected with PBS- or a-MSH-stimulated DCs using antibodies against CD4, Foxp3, and IL-17. One representative image
is shown, and CD4þFoxp3þ regulatory T cells (Tregs) and CD4þ IL-17þ Th17 cells are marked by arrows. Original magnification  400, bar¼ 25mm. DAPI,
40,6-diamidino-2-phenylindole.
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DISCUSSION
Here, we show that a-MSH induced tolerogenic DCs by
decreasing the expression of co-stimulatory molecules
and upregulating the immunosuppressive cytokine IL-10.
Notably, a-MSH-stimulated tolerogenic DCs of murine and
human origin expanded functional Tregs, which efficiently
inhibited the proliferation of effector T cells in vitro, as well
as in vivo. Moreover, a-MSH, by generating Tregs, reduced
the proliferation and cytokine secretion of pathogenic Th17
cells, and thereby ameliorated ongoing psoriasis in a mouse
model. As in mice, a-MSH inhibited the activity of Th17 cells
from individuals with psoriasis, suggesting a-MSH as a
therapeutic option for the treatment of psoriasis, which to
our knowledge is previously unreported.
Upon inflammation, DCs receive maturation signals by a
variety of stimuli, resulting in effector T-cell activation
(Banchereau et al., 2000; Barton and Medzhitov, 2003).
However, immunomodulatory agents have been shown to
induce tolerogenic DCs characterized by a reduced expression
of co-stimulatory receptors and an upregulated secretion of
anti-inflammatory cytokines (Guilliams et al., 2010; Maldona-
do and von Andrian, 2010). Accordingly, the immunomodu-
latory neuropeptide vasoactive intestinal peptide (VIP) inhibits
the capacity of DCs to stimulate effector T cell proliferation by
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Figure 5. a-Melanocyte-stimulating hormone (a-MSH) induces tolerogenic human dendritic cells (DCs) capable of generating functional regulatory T cells
(Tregs). (a) DCs from peripheral blood were stimulated with a-MSH or phosphate-buffered saline (PBS), and the expression of CD80, CD86, and IL-10 was
quantified by flow cytometry. Histogram overlays are gated for HLA-DR, and one representative experiment is shown. IL-10 staining was performed after cell
permeabilization. (b) CD4þ T cells from cocultures with a-MSH-stimulated DCs were analyzed for the expression of Foxp3 and CD25 by flow cytometry. Cells
are gated for CD4; Foxp3 staining was performed after cell permeabilization; and (left) one representative experiment and (right) statistical analyses of n¼ 7
donors are shown (*Po0.05 vs. CD4þ T cells from cocultures with PBS-stimulated DCs). (c) Freshly isolated CD4þCD25 effector T cells were activated with
anti-CD3 and anti-CD28 in the absence or presence of CD4þ T cells from cocultures with PBS- or a-MSH-stimulated DCs. Mean values of 3H-thymidine
incorporation±SD are shown from one out of three independent experiments (*Po0.05 vs. effector T cellsþCD4þ T cells from cocultures with PBS-stimulated
DCs). (d) Signaling via MC-1R is critical for the a-MSH-mediated induction of tolerogenic DCs. HLA-DRþ DCs were purified from peripheral blood of
individuals with loss-of-function variants in the MC-1R gene, stimulated with a-MSH, and the expression of CD86 was analyzed by flow cytometry. Cells are
gated for HLA-DR, and one representative histogram overlay is shown. c.p.m., counts per minute.
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decreasing the expression of CD80 and CD86 and by reducing
the production of pro-inflammatory cytokines (Delgado et al.,
2005b). Similarly, treatment of DCs with NDP-MSH, an analog
of a-MSH and closely related to VIP, downregulates CD86 and
thereby impairs the allostimulatory capacity of DCs (Rennalls
et al., 2010). Recently, a-MSH has been shown to decrease the
expression of CD83 and CD86, thus preventing the maturation
of monocyte-derived DCs (Min et al., 2011). Similar to the
observations made by Rennalls et al. (2010) and Min et al.
(2011), we detected reduced levels of the maturation markers
CD80 and CD86 in a-MSH-stimulated murine and human
DCs, which in combination with the increased IL-10 secretion
points to an immunosuppressive phenotype. Interestingly, in
monocyte-derived DCs the a-MSH-mediated induction of a
tolerogenic phenotype was mediated by the upregulation of
Annexin A1 (Min et al., 2011). Hence, it would be worthwhile
to analyze whether also in murine bmDCs or HLA-DRþ DCs
a-MSH upregulates Annexin A1, thereby providing a possible
explanation why the tolerogenic phenotype of adoptively
transferred DCs was conserved in vivo. However, the
induction of tolerogenic DCs was dependent on a functional
MC-1R as a-MSH neither downregulated co-stimulatory
receptors nor upregulated IL-10 in DCs from C57BL/6Je/e mice
or individuals with variants in theMC-1R gene associated with
a compromised receptor function (Figures 1f and 5c). In
contrast to our observations, Cooper et al. (2005) have shown
that MC-1R variants did not alter a-MSH-induced immuno-
suppression. These inconsistent data might be explained by the
different variant alleles present in the individuals that have
been analyzed. Whereas alleles analyzed by Cooper et al.
(2005) are mainly associated with a red hair/fair skin
phenotype, the variant alleles in our subjects (R151C,
R160W, R142H, and D294H) have been implicated in an
impaired downstream signaling of MC-1R and incomplete
ability to bind a-MSH (Loser et al., 2010).
Immunosuppressive DCs are critically involved in the
induction and maintenance of peripheral tolerance. Although
the detailed mechanism is still unclear, it has been shown
that by repetitive stimulation with tolerogenic DCs CD4þ
T cells differentiate into functional Tregs. Accordingly,
tolerogenic DCs generated by VIP induced the peripheral
expansion of immunosuppressive Tregs, which inhibited
contact allergy (Delgado et al., 2005a). Besides VIP, a-MSH
has been suggested to expand functional Tregs, as CD4þ T
Healthy donors Healthy donors
Individuals with psoriasis Stimulated with PBS
Stimulated with α-MSH
6
6
5
10
8
4
4
3
2
2
1
0
6
5
2
3
4
3
2
1
1
0 0
* *
*
*
0
6
10
12
8
4
2
0
Healthy
donors
Healthy
Individuals
with psoriasis
Psoriasis Healthy Psoriasis Healthy Psoriasis
*%
 IL
-1
7+
 
ce
lls
 in
CD
4+
 
T 
ce
lls
%
 IL
-1
7+
 
ce
lls
 in
CD
4+
 
T 
ce
lls
W/o stimulation
Stimulated with PBS
Stimulated with α-MSH
W/o stimulationStimulated with PBS
Stimulated with α-MSH
W/o stimulation
m
R
N
A 
ex
pr
es
sio
n
(n-
fo
ld
, r
el
at
ive
 
to
 β-
a
ct
in
)
IL-17 IL-22 RORc
Individuals with psoriasis
3H-thymidine 
incorporation (c.p.m. × 103)
100
80
60
40
20
0
* *
w/o
%
 F
ox
p3
+
 
ce
lls
 in
CD
4+
CD
25
+
 
T 
ce
llls
PBS α-MSH
100 20
*
*
*
CD4+CD25–
(Teff)
CD4+CD25+
(PBS) + Teff
CD4+CD25+
(α-MSH) + Teff
30 40 50 60
Figure 6. a-Melanocyte-stimulating hormone (a-MSH)-stimulated DCs induce functional regulatory T cells (Tregs) capable of inhibiting the activity of Th17
cells from individuals with psoriasis. (a) CD4þ T cells were purified from peripheral blood of healthy donors or individuals with psoriasis and cocultured with
a-MSH-stimulated DCs. The numbers of Foxp3þ Tregs were quantified by flow cytometry from n¼8 individuals in each group, and Foxp3 staining was
performed after cell permeabilization. (b) Coculture with a-MSH-stimulated DCs restored the suppressor function in CD4þ T cells from individuals with
psoriasis. Proliferation assays were performed by mixing CD4þ T cells from cocultures with phosphate-buffered saline (PBS)- or a-MSH-stimulated DCs and
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CD4þ T cells from individuals with psoriasis. Subsequently, the numbers of IL-17-expressing cells were quantified by flow cytometry in n¼ 5 individuals in each
group (*Po0.05 vs. coculture with PBS-stimulated DCs). c.p.m., counts per minute.
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cells cocultured in the presence of a-MSH and antigen-
presenting cells inhibited the development of experimental
autoimmune uveoretinitis upon adoptive transfer into immu-
nized mice (Taylor and Namba, 2001). However, the cellular
and molecular mechanism underlying a-MSH-mediated Treg
induction has not been elucidated. Here we show that a-MSH
generates tolerogenic DCs most likely by upregulating IL-10.
The DC-derived IL-10 might directly contribute to Treg
induction, as signaling via the IL-10 receptor has been shown
to over-ride the dephosphorylation of CD28, thereby inhibiting
the secretion of pro-inflammatory cytokines (Maldonado and
von Andrian, 2010). As the IL-10 expression was significantly
increased in mouse and human DCs after stimulation with a-
MSH (Figures 1e and 5a), and as blocking IL-10 signaling
prevented the generation of Tregs (unpublished observation), it
is conceivable that IL-10 might have an important role during
Treg induction by a-MSH-stimulated DCs. Recently, Girard-
Madoux et al. (2012) demonstrated that murine IL-10
receptor–deficient DCs expressed high levels of IL-10 during
CHS, which surprisingly resulted in prolonged and enhanced
contact allergy, suggesting that IL-10 signaling in DCs and
T cells is critical to modulate inflammatory immune responses.
On the basis of these data, it would be interesting to
investigate whether IL-10 secreted by a-MSH-stimulated DCs
primarily modulates T cells or might also be crucial to
maintain the tolerogenic DC phenotype, which could possibly
explain the long-lasting immunosuppressive effect of a-MSH,
although the half-life of this peptide is relatively short (Rudman
et al., 1983).
However, it remained to be clarified whether a-MSH-
stimulated DCs mediated the induction of Tregs from
conventional CD4þCD25 T cells or the expansion of
thymic-derived Tregs. Notably, in cocultures of CD4þ T
cells with a-MSH-stimulated DCs, we observed increased
numbers of Helios induced compared with Heliosþ thymic-
derived Tregs, and, moreover, upon adoptive transfer a-MSH-
stimulated DCs generated Tregs in Treg-depleted mice
(Figure 2f and Supplementary Figure S4 online), suggesting
that a-MSH-treated tolerogenic DCs mediated the de novo
induction rather than the expansion of existing Tregs. In
accordance with our data, Gonzalez-Rey et al. (2006)
demonstrated that VIP administration to CD25-depleted mice
led to the induction of functional CD4þCD25þ Tregs,
indicating that both neuropeptides, VIP and a-MSH, might
promote the peripheral induction of Treg from conventional
T cells. Induced Tregs are a heterogeneous population, but a
common hallmark is the expression of anti-inflammatory
cytokines such as IL-10 and the inhibitory surface receptor
CTLA-4 (Vignali et al., 2008). Similarly, CD4þ T cells from
cocultures with a-MSH-stimulated DCs upregulated CTLA-4
and IL-10 (Figure 2b and c). It is worth noting that direct
stimulation of CD4þ T cells with a-MSH neither resulted in
the upregulation of CTLA-4 and IL-10 nor the induction of
suppressive activity most likely because murine, in contrast to
human, CD4þ T cells did not express MC-1R (Andersen
et al., 2005; Loser et al., 2010).
The anti-inflammatory effects in vivo and the capacity to
induce Tregs suggest melanocortins as potential drugs for the
treatment of inflammatory disorders. Hence, systemic admin-
istration of a-MSH inhibited the development of contact
allergy or reduced gastrointestinal inflammation (Grabbe
et al., 1996; Maaser et al., 2006). Here, we demonstrated that
a-MSH ameliorated ongoing psoriasis-like skin inflammation
in mice and decreased the activity of Th17 cells from
individuals with psoriasis (Figures 3 and 6). The pathogenesis
of psoriasis has been associated with an impaired suppressor
function of Tregs, resulting in the overproduction of pro-
inflammatory cytokines such as TNF-a, IL-17, or IL-22 mainly
by Th1 and Th17 cells (Sugiyama et al., 2005; Nestle et al.,
2009). In this study, we could show that the beneficial effect
of a-MSH was mediated by the induction of tolerogenic DCs
and functional Tregs, which downregulated the proliferation
and cytokine secretion of human and murine Th17 cells and
thereby ameliorated disease, thus suggesting a-MSH as a
potential therapeutic alternative for the treatment of indivi-
duals with psoriasis. Long-term TNF-a inhibitor treatment of
individuals with psoriasis exacerbated disease in some cases
(Ko et al., 2009), and analyses in a mouse model revealed
that this might be mediated by a decrease in Treg numbers
(Ma et al., 2010). On the basis of our data, it is conceivable
that in psoriasis treatment a-MSH could shift the immune
responses from a Th17-dominated inflammation back to a
tolerance-controlled status by expanding functional Tregs
through the induction of tolerogenic DCs.
MATERIALS AND METHODS
Materials and Methods can be found in the Supplementary
Information online.
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